Persistent Fetal Circulation Syndrome D010547

Diseases [C] » Respiratory Tract Diseases [C08] » Lung Diseases » Hypertension, Pulmonary » Persistent Fetal Circulation Syndrome

Diseases [C] » Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] » Infant, Newborn, Diseases » Persistent Fetal Circulation Syndrome

Description

A syndrome of persistent PULMONARY HYPERTENSION in the newborn infant (INFANT, NEWBORN) without demonstrable HEART DISEASES. This neonatal condition can be caused by severe pulmonary vasoconstriction (reactive type), hypertrophy of pulmonary arterial muscle (hypertrophic type), or abnormally developed pulmonary arterioles (hypoplastic type). The newborn patient exhibits CYANOSIS and ACIDOSIS due to the persistence of fetal circulatory pattern of right-to-left shunting of blood through a patent ductus arteriosus (DUCTUS ARTERIOSUS, PATENT) and at times a patent foramen ovale (FORAMEN OVALE, PATENT).   MeSH

Hierarchy View

View MeSH Tree View ICD-10 Tree

Approved Indicated Drugs (1)

tolazoline

Phase 4 Indicated Drugs (5)

nitric oxide (inomax)

nitrogen

nitrous oxide

oxygen

sildenafil (viagra)

Other Experimental Indicated Drugs (1)

milrinone (primacor)


Organization Involved with Phase 4 Indications (5)

Govt Medical College, Bhavnagar

Mallinckrodt

Sir Takhtasinhji General Hospital

University of Alabama, Birmingham

University of Florida

Organization Involved with Phase 3 Indications (34)

Actelion

Baylor University

Brown University

Canadian Institutes of Health Research (CIHR)

Case Western Reserve University

Cornell University

Emory University

George Washington University

Hamad Medical Corporation

Health Sciences Centre Foundation, Manitoba

Indiana University

McGill University

McMaster University

Medical Research Council of Canada

National Center for Research Resources (NCRR)

National Institute of Child Health and Human Development (NICHD)

Pfizer

Stanford University

The University of Texas, Dallas

University of British Columbia

University of Calgary

University of California, San Diego

University of Cincinnati

University of Miami

University of New Mexico

University of Ottawa

University of Saskatchewan

University of Sydney

University of Tennessee

University of Texas at Houston

University of Washington

University of Wisconsin

Wayne State University

Yale University

Organization Involved with Phase 2 Indications (4)

National Institutes of Health (NIH)

Sohag University

State University of New York, Buffalo

United Therapeutics

Organization Involved with Phase 1 Indications (3)

Duke University

The EMMES Corporation

University of North Carolina at Chapel Hill

Organization Involved with Other Experimental Indications (4)

American Medical Association

Bedford Pharmaceuticals

Thrasher Research Fund

University of Pennsylvania

Hierarchy Tree View

UMLS Data


YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.